FDA approves Vabomere (meropenem + vaborbactam) (formerly Carbavance) to treat urinary tract infections.-Rempex Pharmaceuticals/The Medicines Company.
The FDA approved Vabomere (meropenem + vaborbactam)( formerly Carbavance),from Rempex Pharmaceuticals, for adults with complicated urinary tract infections (cUTI), including a type of kidney infection, pyelonephritis, caused by specific bacteria. Vabomere is a drug containing meropenem, an antibacterial, and vaborbactam, which inhibits certain types of resistance mechanisms used by bacteria. To reduce the development of drug-resistant bacteria and maintain the effectiveness of antibacterial drugs, Vabomere should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria.
Vabomere was designated as a qualified infectious disease product (QIDP). This designation is given to antibacterial products that treat serious or life-threatening infections under the Generating Antibiotic Incentives Now (GAIN) title of the FDA Safety and Innovation Act. As part of its QIDP designation, Vabomere received a priority review.
Comment: Rempex Pharmaceuticals was acquired by The Medicines Company in December 2013.